Progenitor cell therapy improves motor function in patients with spinal cord injury

This article was originally published here

Progenitor cell therapy improves motor function in patients with spinal cord injuryShares in Asterias Biotherapeutics (NYSE:AST) jumped 11% today to $3.53 apiece after the company reported positive data for its AST-OPC1 progenitor cell therapy in patients with spinal cord injuries.

The Phase 1/2A clinical trial includes 6 patients in the AIS-A 10 million cell cohort. The company’s AST-OPC1 progenitor cell therapy is derived from human embryonic stem cells and has been shown to produce neurotrophic factors, stimulate vascularization and induce remyelination of denuded axons in animal models – functions that are critical for restoring nerve impulses in patients with spinal cord injuries, according to Asterias.

Get the full story at our sister site, Drug Delivery Business News.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply